- Home
- MAX vs PHAR Comparison
MAX vs PHAR Comparison
Compare MAX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- PHAR
- Stock Information
- Founded
- MAX 2014
- PHAR 1988
- Country
- MAX United States
- PHAR Netherlands
- Employees
- MAX N/A
- PHAR N/A
- Industry
- MAX Industrial Machinery/Components
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- PHAR Health Care
- Exchange
- MAX Nasdaq
- PHAR Nasdaq
- Market Cap
- MAX 604.9M
- PHAR 618.3M
- IPO Year
- MAX 2020
- PHAR N/A
- Fundamental
- Price
- MAX $11.77
- PHAR $8.20
- Analyst Decision
- MAX Buy
- PHAR Strong Buy
- Analyst Count
- MAX 8
- PHAR 3
- Target Price
- MAX $22.00
- PHAR $27.00
- AVG Volume (30 Days)
- MAX 375.8K
- PHAR 5.6K
- Earning Date
- MAX 02-24-2025
- PHAR 03-13-2025
- Dividend Yield
- MAX N/A
- PHAR N/A
- EPS Growth
- MAX N/A
- PHAR N/A
- EPS
- MAX 0.19
- PHAR N/A
- Revenue
- MAX $681,230,000.00
- PHAR $285,745,000.00
- Revenue This Year
- MAX $122.48
- PHAR $20.08
- Revenue Next Year
- MAX $32.24
- PHAR $9.22
- P/E Ratio
- MAX $62.34
- PHAR N/A
- Revenue Growth
- MAX 72.47
- PHAR 30.64
- 52 Week Low
- MAX $10.21
- PHAR $6.65
- 52 Week High
- MAX $25.78
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- MAX 55.43
- PHAR 36.29
- Support Level
- MAX $11.02
- PHAR $8.49
- Resistance Level
- MAX $11.73
- PHAR $9.35
- Average True Range (ATR)
- MAX 0.45
- PHAR 0.55
- MACD
- MAX 0.09
- PHAR -0.17
- Stochastic Oscillator
- MAX 75.00
- PHAR 12.14
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.